好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Hypertensive Disorders in Pregnancy and Future Development of Dementia: A Systematic Review and Meta-analysis
Aging, Dementia, and Behavioral Neurology
P1 - Poster Session 1 (9:00 AM-5:00 PM)
021

We aimed to evaluate the association between hypertensive disorders in pregnancy and future risk of cognitive impairment and dementia.

 

 

Hypertensive disorders of pregnancy (HDP) are a unique vascular risk factor among women. Given the strong association of other vascular risk factors with dementia, it is possible that HDP may also place women at a greater risk of dementia in later life.

In this meta-analysis (PROSPERO CRD42020179272, MOOSE-compliant), systematic searches were performed in MEDLINE and EMBASE for studies examining cognitive outcomes in women with HDP. Exposure of interest included the different types of HDP. Outcomes of interest included dementia incidence, dementia subtype, and cognitive testing. Pooled hazard ratios (aHR) with 95% confidence intervals were adjusted for age at delivery, ethnicity, and vascular risk factors.
On qualitative review, 4 out of 9 included studies showed impaired memory, visual motor processing speed, executive function, and verbal testing in previously preeclamptic women. Two of 4 studies showed impaired visual motor processing and subjective cognitive complaints in previously eclamptic women. Six cohort studies involving >2.6 million women were included in the meta-analysis. Women with a history of gestational hypertension were more likely to develop vascular dementia (aHR 2.02 [1.45-2.83]), but not Alzheimer disease (1.24 [0.93-1.66],single-study). Women with a history of preeclampsia were also more likely to develop vascular dementia (2.17 [1.20-3.91],I2:61.1%), but not Alzheimer dementia (1.19 [0.83-1.69],I2:69.9%). 
Whereas studies of neuropsychological testing in previously preeclamptic and eclamptic women have been heterogeneous, a history of HDP is associated with developing vascular dementia in later life.
Authors/Disclosures
Aaron R. Switzer, MD
PRESENTER 		Dr. Switzer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eisai Company Limited.
Eric E. Smith, MD (University of Calgary) Dr. Smith has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Heart Association. Dr. Smith has received publishing royalties from a publication relating to health care. Dr. Smith has received publishing royalties from a publication relating to health care.
Aravind Ganesh, MD (Department of Clinical Neurosciences, University of Calgary) Dr. Ganesh has received personal compensation in the range of $0-$499 for serving as a Consultant for Figure 1. Dr. Ganesh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Servier Canada. Dr. Ganesh has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eisai. Dr. Ganesh has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli-Lilly. Dr. Ganesh has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Let's Get Proof (Collavidence Inc). Dr. Ganesh has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for 好色先生 (journals Neurology and Neurology: Clinical Practice). Dr. Ganesh has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Heart Association (journal: Stroke). Dr. Ganesh has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Frontiers (for Frontiers in Neurology). Dr. Ganesh has or had stock in SnapDx.Dr. Ganesh has or had stock in Collavidence Inc.Dr. Ganesh has or had stock in DataSimpl. The institution of Dr. Ganesh has received research support from Canadian Institutes of Health Research . The institution of Dr. Ganesh has received research support from Alberta Innovates. The institution of Dr. Ganesh has received research support from University of Calgary Centre for Clinical Research. The institution of Dr. Ganesh has received research support from Innovation 4 Health. The institution of Dr. Ganesh has received research support from Government of Canada INOVAIT. The institution of Dr. Ganesh has received research support from Campus Alberta Neuroscience. The institution of Dr. Ganesh has received research support from Alzheimer Society of Canada. The institution of Dr. Ganesh has received research support from Heart and Stroke Foundation of Canada. The institution of Dr. Ganesh has received research support from New Frontiers in Research Fund. The institution of Dr. Ganesh has received research support from Panmure House. The institution of Dr. Ganesh has received research support from Brain Canada. The institution of Dr. Ganesh has received research support from MSI Foundation. The institution of Dr. Ganesh has received research support from France Canada Research Fund. Dr. Ganesh has received intellectual property interests from a discovery or technology relating to health care.